natera™ | Panorama™
Next-generation NIPT

Every pregnancy deserves Panorama

Screening for a more informed pregnancy

NATERA
10 years
Panorama NIPT

The only SNP-based NIPT

Panorama's single nucleotide polymorphism (SNP)—based noninvasive prenatal test (NIPT) distinguishes between the maternal and fetal (placental) DNA and delivers unique, clinically validated capabilities.[1–27]

SNPs

Panorama evaluates SNPs — the 1% of our DNA that makes us different from one another.



Counting NIPTs

Other NIPTs look at DNA in aggregate.



Panorama screens for:

	Singleton	Monozygotic twins	Dizygotic twins	Singleton egg donor and gestational carrier
Trisomies 21, 18, 13	✓	✓	✓	✓
Monosomy X	✓	✓		
Sex chromosome trisomies	✓	✓		
22q11.2 deletion syndrome (22q11.2DS), optional	✓	✓		
Additional microdeletion syndromes, optional	✓			
Fetal sex, optional	✓	✓	✓	✓
Individual fetal sex, optional			✓	
Zygosity		✓	✓	
Individual fetal fraction			✓	
Triploidy	✓			

For a complete list of Panorama's performance metrics, including positive predictive value (PPV), scan here

Panorama only[7–10]

Delivering more insights with high accuracy

With more than 3 million tests performed, Panorama delivers high accuracy, reliability, and unique twins differentiation to make every result matter.[1–27]



#1* for a reason[13]

TESTS
3 MILLION+
performed

PATIENTS
1.3 MILLION+
studied

PUBLICATIONS
25+

*in the US

Improving performance through continuous innovation

Panorama AI, the latest version of Panorama, combines artificial intelligence with Natera's proprietary SNP-based methodology to deliver results, even in difficult-to-call cases.

- Maintains high accuracy while significantly lowering "no-call" rates[1]
- Increases accuracy for 22q11.2 deletion detection[5]

SMART, the largest prospective NIPT study

- Included a large cohort of average-risk pregnancies[1]
- Validated that Panorama's latest version delivers high sensitivity and specificity in clinical settings, while significantly lowering "no-call" rates[1,5,6]

SMART
SNP-based Microdeletion and Aneuploidy RegisTry

Scan here to learn more about the SMART study

PATIENTS	SITES	OUTCOMES
20,000+ enrolled	21 global centers	100% of patients included in analysis had genetic confirmation

High accuracy. Fewer "no-calls"

Validated in the SMART study, the latest version of Panorama has a significantly lower "no-call" rate while continuing to deliver high accuracy.[1]





*Trisomies 21, 18, and 13 combined.

22q11.2 deletion screening with actionable results

Panorama was validated in SMART with high accuracy and positive predictive value (PPV) for 22q11.2 deletions.[1,5,6]

>99.9%
sensitivity
Most common deletion size (2.5 Mb+)

83%
sensitivity
Full and nested deletions (0.5 Mb+)

53%
PPV
Full and nested deletions (0.5 Mb+)

Mb= Megabase pair

> ***"22q11.2DS is associated with severe morbidity, has reasonably high prevalence, is usually not otherwise reliably detected, can be confirmed with diagnostic testing, and outcomes can be improved with early diagnosis. It would seem that this disorder is an appropriate target for routine prenatal screening."***[28]
>
> PE'ER DAR, MD & MARY NORTON, MD

22q11.2DS prevalence in early pregnancy compared to commonly screened conditions[5,29–33]



Prevalence of conditions associated with 22q11.2DS[34–38]



Perinatal interventions key to better outcomes[34–38]

- Delivery at tertiary center
- Calcium-level monitoring at birth
- Delayed live-vaccine administration
- Palatal evaluation for potential feeding and breathing issues

Panorama continues to deliver

High performance in singleton pregnancies[1]



Greater clarity for twins

Knowing zygosity is important for managing twin pregnancies[8, 39-43, 45]



*TTTS, Twin-to-twin transfusion syndrome

Every pregnancy deserves Panorama

> ***"Cell-free DNA [NIPT] is the most sensitive and specific screening test for the common fetal aneuploidies ... [It] should be discussed and offered to all patients early in pregnancy regardless of maternal age or baseline risk."***[45]
>
> ACOG PRACTICE BULLETIN 226

ACOG guidelines highlights, including unique capabilities of SNP-based NIPT

ACOG PRACTICE BULLETIN 226 HIGHLIGHTS[45]	PANORAMA SNP-BASED NIPT[1–4,7–12]
Highlights known sources of false positives for most NIPTs: • **Vanishing twin** • **Maternal mosaicism**	**Addressed**
"Of the [NIPT] *methods, the* [SNP-based] *method can* ***identify triploidy****."*	✓
"The lower prevalence of fetal trisomies in ***younger patients*** *results in...a* ***lower PPV****..."*	**Clinical PPVs published**
"Cell-free DNA [NIPT] *can be* ***performed in twin pregnancies****".*	✓
"One laboratory method which uses ***SNP analysis reports zygosity as well as individual fetal fractions****."* *"*[In twin gestations,] *it is possible that an* ***aneuploid fetus would contribute less fetal DNA****, therefore masking the aneuploid result."*	✓

Panorama's areas of unique clinical value

- Every result matters
- Accuracy and reliability
- Twins differentiation

Trisomy 21 PPVs by age groups, shown in a large study of 1M patient outcomes[12,13]



Regardless of age, strong clinical evidence of greater than 90% PPV for trisomy 21

Support every step of the way

Education

Patient-friendly materials and information sessions, covering basic genetics to specific tests

Results

Clear, actionable reports, complete with on call expert guidance

Next steps

Value-add services that go beyond the test to address what's next

Pre- and post-test genetic information sessions
– with board-certified genetic counselors, complimentary to all providers and patients

References

1. Dar et al. Am J Obstet Gynecol. Published online January 24, 2022. doi:10.1016/j.ajog.2022.01.019
2. Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8.
3. Nicolaides et al. Prenat Diagn. 2013 Jun; 33(6):575-9.
4. Ryan et al. Fetal Diagn Ther. 2016; 40(3):219-23.
5. Dar et al. Am J Obstet Gynecol. Published online January 13, 2022. doi:10.1016/j.ajog.2022.01.002
6. Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies, SFMS's 40th Annual Pregnancy Meeting 2021.
7. Norwitz et al. J Clin Med. 2019 Jun; 8:937.
8. Hedriana et al. Prenat Diagn. 2020 Jan; 40(2):179-84.
9. Nicolaides et al. Fetal Diagn Ther. 2014; 35(3):212-7.
10. McKanna et al. Ultrasound Obstet Gynecol. 2019 Jan; 53(1):73–79.
11. Martin et al. Am J Obstet Gynecol MFM. 2020 Aug; 2:100152.
12. DiNonno.et al. J Clin Med. 2019 Aug; 8(9),1311.
13. Internal data, Natera.
14. Stokowski et al. Prenat Diagn. 2015 Dec; 35(12):1243-6.
15. Jones et al. Ultrasound Obstet Gynecol. 2018 Feb; 51(2):275-6.
16. Hooks et al. Prenat Diagn. 2014 May; 34(5):496-9.
17. Schmid et al. Fetal Diagn Ther. 2018; 44(4):299-304.
18. Palomaki et al. Genet Med. 2011 Nov; 13(11):913-20.
19. Palomaki et al. Genet Med. 2012 Mar; 14(3):296-305.
20. Porreco et al. Am J Obstet Gynecol. 2014 Oct; 211(4):365 e1-12.
21. Mazloom et. al. Prenat Diagn. 2013 Jun; 33(6):591-7.
22. Tynan et al. SMFM 37th Annual Pregnancy Meeting 2017.
23. Sehnert et al. Clin Chem. 2011 Jun; 57(7):1042-9.
24. Bianchi et al. Obstet Gynecol. 2012 May; 119(5):890-901.
25. Bianchi et al. N Engl J Med. 2014 Feb; 370(9):799-808.
26. Verinata Health. Analytical validation of the Verifi prenatal test, 2012.
27. The commercial protocol is not validated. Illumina marketing materials cite Srinivasan et al. Am J Hum Genet. 2013 Feb; 92(2):167-76, which does not match the number of reads used in commercial testing.
28. Dar and Norton. Am J Obstet Gynecol. 2022. Epub prior to publication. doi: https://doi.org/10.1016/j.ajog.2022.01.036.
29. Maternal age-related risk for common fetal trisomies across pregnancy. UpToDate. Accessed January 20, 2022. https://www.uptodate.com/contents image?imageKey=OBGYN%2F75423
30. Martin et al. Natl Vital Stat Rep. 2021 Apr; 70(2):1-51. doi: https://dx.doi.org/10.15620/cdc:100472.
31. Hamosh et al. J Pediatr. 1998 Feb; 132(2):255-9.
32. O'Sullivan, Freedman. Lancet. 2009 May; 373(9678):1891-904.
33. Prior et al. Spinal muscular atrophy. In: Adam et al, eds. GeneReviews. University of Washington; 2000.
34. Bassett et al. J Pediatr. 2011 Aug; 159(2):332-9.e1.
35. Cheung et al. Genet Med. 2014 Jan; 16(1):40-4.
36. Grand et al. Am J Med Genet A. 2018 Oct; 176(10):2167-71.
37. Palmer et al. Am J Med Genet A. 2018 Apr; 176(4):936-44.
38. McDonald-McGinn et al. 22q11.2 Deletion Syndrome. In: Adam et al., editors. GeneReviews. University of Washington, 1993-2022.
39. Society for Maternal-Fetal Medicine, Clinical guideline: Twin-twin transfusion syndrome, Jan 2013.
40. American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine, practice bulletin #169, Oct 2016.
41. Oldenburg et al. Ultrasound Obstet Gynecol. 2012 Jan; 39(1); 39: 69–74.
42. Chasen, Chervenak (2017). Twin pregnancy: Prenatal issues. In T. Post (Ed.), UpToDate. Waltham, Mass.: UpToDate. Retrieved from www.uptodate.com
43. Cunningham et al. Williams Obstetrics. 24th edition. New York: McGraw-Hill Education, 2014.
44. Blumenfeld et al. J Ultrasound Med. 2014 Dec; 33(12):2187- 92. Edited 04/15/22
45. American College of Obstetricians and Gynecologists, practice bulletin #226, October 2020.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

natera™